Meanwhile, at CML diagnosis, NGS is recommended to detect both BCR::ABL1 fusion transcripts and additional mutations that may impact prognosis and treatment selection. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.